Company news
Allergy Therapeutics Plc (LSE:AGY) news
Allergy Therapeutics Plc news releases on 6ix. Latest, Oct 9, 2020: Director Dealings and Issue of Equity
Press releases — page 4
Director Dealings and Issue of Equity
October 9, 2020
Preliminary Results
September 23, 2020
AGY secures VLP technology platform
September 3, 2020
Allergy Therapeutics (AGY): Record sales and a ...
July 20, 2020
Invalidation of Birch MATA MPL phase III results
July 9, 2020
BLOCK LISTING SIX MONTHLY RETURN
July 1, 2020
EAACI review of adjuvants and formulations
April 22, 2020
Grant and Vesting of Awards
April 1, 2020
Allergy Therapeutics (AGY): Consistent first-ha...
March 9, 2020
Half-year Report
March 4, 2020
Data for peanut allergy vaccine published in JACI
January 29, 2020
Trading Update & Notice of Results - Replacement
January 16, 2020
Allergy Therapeutics (AGY): Sales growth well a...
January 16, 2020
Holdings in Company
December 2, 2019
Update to Grass MATA MPL Ph III clinical programme
November 26, 2019
Annual Report and Accounts
October 22, 2019
Allergy Therapeutics (AGY): Continuing to gain ...
September 26, 2019
Trading update
July 11, 2019
Allergy Therapeutics (AGY): Successful legal ou...
July 1, 2019
Oxford BioMedica (OXB): Eying up long-term value
July 1, 2019
Trading Statement
June 27, 2019
Successful Litigation Settlement
June 27, 2019
Board Change
June 19, 2019
Titon Holdings Plc (TON): You need hands
May 21, 2019
Allergy Therapeutics (AGY): House dust mite vac...
May 21, 2019
Positive top line phase I results for Acarovac MPL
May 20, 2019
Research Published on Adjuvant Systems
May 7, 2019
Regulatory and Trading Update
April 25, 2019
Allergy Therapeutics (AGY): Take an objective view
March 18, 2019
Top Line Phase III results from B301 trial
March 18, 2019
Allergy Therapeutics (AGY): Strong operating pe...
March 6, 2019
Interim Results
March 6, 2019
Allergy Therapeutics (AGY): Trading update: gai...
January 17, 2019
Trading Update & Notice of Results
January 16, 2019
AGM Trading Update
November 27, 2018
Presentation at Jefferies Healthcare Conference
November 12, 2018
Directorate Change
November 8, 2018
Allergy Therapeutics (AGY): 2018 full-year resu...
September 27, 2018
Notice of Results
August 8, 2018
Results of Placing and Subscription
July 19, 2018
Proposed placing & subscription to raise £10.6m
July 19, 2018
Allergy Therapeutics (AGY): Steady performance ...
July 13, 2018
Positive data of Pollinex Quattro Grass vaccine
June 25, 2018
Positive data with house-dust mite immunotherapy
May 29, 2018
Allergy Therapeutics (AGY): Opening the door to...
May 21, 2018
Positive top-line results from Grass Ph II study
May 21, 2018
Publication of MCT Adjuvant Data
May 14, 2018
Hardman: Clinical development towards submission
March 7, 2018
Polyvac® Peanut CMO appointed
February 28, 2018
Completion of recruitment in PQ Grass Ph II trial
February 12, 2018